Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 11/12/2024 at 14:20, 8 days 23 hours ago

Moderna Tops BioSpace's Best Places to Work for Fourth Year

Innovation AI Integration Life Sciences Moderna Workplace Ranking
PRESS RELEASE

published on 11/12/2024 at 14:15, 8 days 23 hours ago

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Moderna, Inc. named top large employer in BioSpace's 2025 Best Places to Work report for fourth consecutive year. Company's commitment to innovation recognized

Innovation Best Places To Work Moderna Employee Recognition BioSpace
BRIEF

published on 11/08/2024 at 13:35, 13 days ago

Moderna Secures Health Canada Approval for RSV Vaccine for Seniors

Health Canada MRNA Technology Moderna RSV Vaccine MRESVIA
PRESS RELEASE

published on 11/08/2024 at 13:30, 13 days ago

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Health Canada approves Moderna's mRESVIA, a single-dose mRNA vaccine against RSV for adults aged 60 and older in a convenient pre-filled syringe. The vaccine's approval follows successful Phase 3 trial ConquerRSV

Health Canada MRNA Technology Moderna RSV Vaccine MRESVIA
BRIEF

published on 11/07/2024 at 12:35, 14 days 1 hour ago

Moderna Reveals Third Quarter 2024 Financial Performance Alongside Strategic Developments

Financial Results Moderna Product Sales MRNA Vaccines Executive Expansion
PRESS RELEASE

published on 11/07/2024 at 12:30, 14 days 1 hour ago

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q3 revenue of $1.9B, net income of $13M, and EPS of $0.03. Initiates Phase 3 trials for mRNA vaccines, reiterates 2024 sales guidance. Announces expansion of Executive Committee

Revenue Executive Committee Moderna Vaccines Q3
BRIEF

published on 10/31/2024 at 12:05, 21 days 2 hours ago

Moderna to Participate in November 2024 Investor Conferences

Investor Conferences Healthcare Innovation MRNA Technology Moderna Webcast Access
PRESS RELEASE

published on 10/31/2024 at 12:00, 21 days 2 hours ago

Moderna to Present at Upcoming Conferences in November 2024
Moderna, Inc. to participate in upcoming investor conferences: Guggenheim's Healthcare Innovation Conference, UBS Global Healthcare Conference, Jefferies London Healthcare Conference. Moderna leading in mRNA medicine technology for disease treatment and prevention

Investor Conferences Healthcare Innovation MRNA Medicine Moderna Disease Treatment
BRIEF

published on 10/24/2024 at 20:30, 27 days 17 hours ago

Moderna Recognized as Top Employer for Tenth Consecutive Year

Innovation Biopharmaceutical Moderna ChatGPT Top Employer
PRESS RELEASE

published on 10/24/2024 at 20:25, 27 days 17 hours ago

Moderna Named a Top Employer by Science for Tenth Consecutive Year
Moderna, Inc. ranked as a top employer in global biopharmaceutical industry for tenth consecutive year. Acknowledged for innovation, employee respect, and social responsibility

Biopharmaceutical Industry Moderna ESG Report Top Employer Science Survey

Accesswire

Published on 11/21/2024 at 13:30, 35 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 35 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 5 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 50 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 30 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 50 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 59 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 2 hours 5 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 7 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 45 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 20 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 20 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE